Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18770255 | 0.87 | CALML3 (0.55) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL18770250 | 0.87 | CALML3 (0.55) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL10197347 | 0.85 | CALML3 (0.61) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL10197541 | 0.84 | CALML3 (0.72) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL11983122 | 0.83 | CALML3 (0.61) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL13944871 | 0.83 | MAOB (0.54) | CALML3CYP2C19MAOAMAOBCYP2C9 | |
| SCHEMBL1222291 | 0.82 | MAOB (0.50) | CALML3MAOAMAOB | |
| SCHEMBL1222294 | 0.82 | MAOB (0.50) | CALML3MAOAMAOB | |
| SCHEMBL13944982 | 0.81 | MAOB (0.52) | CALML3MAOAMAOB | |
| SCHEMBL13944874 | 0.81 | MAOB (0.51) | CALML3CYP2C19MAOAMAOBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885CYP2C19 1321/4885CYP3A4 793/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885CYP2C19 1321/4885CYP3A4 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.